Long-Course RT Better at Organ-Sparing in Rectal Cancer Long-Course RT Better at Organ-Sparing in Rectal Cancer
Long-course radiation therapy for rectal cancer is more likely to spare organs than short-course therapy is, including when chemotherapy is given first as part of a total neoadjuvant therapy strategy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemo Improves Colon Cancer Outcomes
WEDNESDAY, Feb. 1, 2023 -- Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy is safe and effective for operable colon cancer, without increasing perioperative morbidity, according to a study published online Jan. 19 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2023 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemo Reduces Disease Recurrence in Operable Colon Cancer
(MedPage Today) -- Six weeks of neoadjuvant chemotherapy for patients with operable colon cancer is safe and results in downstaging, increased complete resection rates, and better disease control at 2 years, according to results from the randomized... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 24, 2023 Category: Surgery Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

Recurrence Score Indicates When to Use Endocrine Therapy Recurrence Score Indicates When to Use Endocrine Therapy
Scores on a breast recurrence assay may signal which patients can get neoadjuvant endocrine therapy vs chemotherapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Optimal Surgery Timing After Chemo in Esophageal Cancer? Optimal Surgery Timing After Chemo in Esophageal Cancer?
New data show that survival outcomes were best when surgery came 6 –8 weeks after neoadjuvant chemotherapy. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mesothelioma Surgery With Immunotherapy Proves Effective in Study
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine. The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective. This randomized clinical trial compared the use of durvalumab alone – already shown to be effective in other cancers – to both the two-drug combination and to using no immunotherapy before mesothelioma surgery. Clinica...
Source: Asbestos and Mesothelioma News - December 19, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news

Marker May Explain Poor Outcomes in Black Breast Cancer Patients Marker May Explain Poor Outcomes in Black Breast Cancer Patients
A study of tumor microenvironments suggests that breast tumors in Black women may have a stronger prometastatic response to neoadjuvant chemotherapy than tumors in White women.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Debulking Surgery Should Come Soon After NACT in Ovarian Cancer Debulking Surgery Should Come Soon After NACT in Ovarian Cancer
Survival outcomes were better when debulking surgery was performed within 4 weeks of neoadjuvant chemotherapy (NACT), according to a study that was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Response to Neoadjuvant Chemo for Breast Cancer Varies by Sex
Men have lower rates of pathologic complete response than women across tumor subtypes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Neoadjuvant CRT Tied to Survival Benefit in Older Rectal Cancer Patients
(MedPage Today) -- Neoadjuvant chemoradiation therapy (CRT) followed by surgical resection was associated with a survival benefit in elderly patients with locally advanced rectal cancer compared with other treatment sequences, according to a retrospective... (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 6, 2022 Category: Radiology Source Type: news

Response to Neoadjuvant Chemo for Breast Cancer Varies by Sex
THURSDAY, Oct. 6, 2022 -- Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2022 Category: Pharmaceuticals Source Type: news

Galunisertib Added to Standard Treatment Promising in Rectal Cancer
(MedPage Today) -- Adding the investigational TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy was associated with improved response rates in patients with locally advanced rectal cancer compared with historical... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 3, 2022 Category: Gastroenterology Source Type: news

Efficacy of Durvalumab for Early-Stage TNBC Examined by Race
FRIDAY, Aug. 19, 2022 -- Among patients with early-stage triple-negative breast cancer (TNBC), the pathologic complete response (pCR) rate for durvalumab added to neoadjuvant chemotherapy is 46 percent, with similar rates for African American (AA)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2022 Category: Pharmaceuticals Source Type: news